RxDoctor Payments Data

Seth Greenberg, MD

Pulmonary Disease · Virginia Beach, VANPI 1467552497

Payments from drug & device makers

$7,659in general payments, 2019–2025

Across 408 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$1K
  • Sanofi$439
  • Mallinckrodt Hospital Products Inc.$418
  • Boehringer Ingelheim$407
  • Inspire Medical Systems, Inc.$349
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$7,627100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,659 in reported general payments places this provider in the 65th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$161,086
Medicare patients
659
Services billed
2,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter161$170,092
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr63$41,375
Spiriva RespimatTiotropium Bromide24$21,328
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$19,085
Spiriva HandihalerTiotropium Bromide13$15,440
Breo ElliptaFluticasone/Vilanterol26$14,898
Albuterol Sulfate HfaAlbuterol Sulfate137$6,006
DuleraMometasone/Formoterol15$5,029
Wixela InhubFluticasone Propion/Salmeterol14$3,663
Arnuity ElliptaFluticasone Furoate12$2,753
Roflumilast12$1,604
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$1,555
Montelukast Sodium80$739
Prednisone74$498
Azelastine Hcl14$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$1,199$229,119262 claims
Boehringer IngelheimSpiriva Respimat$407$21,32824 claims
AstraZenecaBreztri Aerosphere$1,082$19,08518 claims
MerckDulera$77$5,02915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →